Hovione and Zerion Pharma announce a strategic partnership to market the Dispersome(R) technology platform
PR94632
LISBON, Portugal Feb. 22, 2022 /PRNewswire=KYODO JBN/ --
Hovione, the leader in spray drying and particle engineering, announced today a
strategic partnership with Zerion Pharma to market and commercialize
Dispersome(R), Zerion´s proprietary solubility enhancement technology platform.
Zerion´s innovative Dispersome(R) technology builds on a new concept of
increasing drug solubility by using natural protein-based excipients to
formulate APIs into amorphous solid dispersions (ASDs) by spray drying. By
combining Dispersome(R) technology with Hovione's unique spray drying
capabilities, experience in development, scale-up and GMP manufacturing,
Hovione further strengthens its leadership in amorphous solid dispersions and
shows its commitment to innovative solutions to overcome one of the most
prevalent challenges faced by the industry: low drug solubility.
"We are extremely pleased to have entered into this partnership with Zerion
whom we recognize as a very innovative company in the field of oral drug
formulations. By joining forces, Zerion and Hovione will be able to bring
Dispersome(R) to the market faster. We look forward to applying the technology
in collaboration with our customers and partners in our effort to develop novel
drugs with strong benefits to patients.", comments Jean-Luc Herbeaux, Hovione´s
Chief Operating Officer. "Hovione will continue to pursue opportunities to
enhance its offering around core areas of expertise such as particle
engineering and inhalation by partnering with companies and research
institutions developing innovative drug formulation technologies, like
Dispersome(R)".
Zerion´s CEO, Ole Wiborg, sees a strong synergy in the partnership and expects
it to generate new pharma partnerships. "We consider Hovione the global leader
in the field of producing amorphous solid dispersions by spray-drying. More
importantly for us, this leadership has resulted in Hovione being, over the
last 5 years, the main commercial manufacturer of novel FDA-approved drugs
formulated as amorphous solid dispersions. Incorporating these competencies in
our offering to the pharma industry both validates the strength of our
Dispersome(R) platform and provides us and our pharma partners immediate access
to the highest quality in upscaling and commercial GMP manufacturing." says Ole
Wiborg.
The announcement of this partnership follows Hovione's communication on a
further expansion with an expected investment of $170 million in assets
worldwide and shows the company's commitment to also expand its technology
platforms. Hovione is investing both in new assets and innovative technologies
to meet customer demand for integrated and differentiated services in drug
substance manufacturing, particle engineering and most recently drug product
manufacturing.
About Hovione
Hovione is an international company with over 60 years of experience as a
Contract Development and Manufacturing Organization (CDMO) with a fully
integrated offering of services for drug substance, drug product intermediate
and drug product. The company has four FDA inspected sites in the USA,
Portugal, Ireland and China and development laboratories in Lisbon, Portugal
and New Jersey, USA. Hovione provides pharmaceutical customers services for the
development and compliant manufacture of innovative drugs, including highly
potent compounds, and customized product solution across the entire drug life
cycle. In the inhalation area, Hovione is the only independent company offering
a complete range of services, from API, formulation development and devices.
Hovione is a company with a culture based on innovation, quality and delivery.
Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B
Corp, is a member of Rx-360, EFCG and participates actively in industry quality
improvement initiatives to lead new global industry standards.
About Zerion Pharma ApS
Zerion has pioneered the Dispersome(R) technology that greatly enhances the
solubility of poorly soluble, oral drugs and improves bioavailability and
therapeutic outcomes for the patients. The Dispersome(R) technology is based on
preparing stable amorphous formulations by mixing high loads of the drug
compound with beta-lactoglobulin, a sustainable and biodegradable by-product
from cheese production. Zerion develops proprietary drug formulations and
offers the Dispersome(R) technology to established pharma companies as a means
to solve their most challenging drug solubility problems.
Zerion was established in 2019 as a spinout from the University of Copenhagen
based on almost a decade of research.
(Dispersome(R) is a trademark of Zerion Pharma A/S)
Logo - https://mma.prnewswire.com/media/1686008/Logo_Hovione_Logo.jpg
For more information, please visit www.hovione.com or contact:
Isabel Pina | Director External Communications | ipina@hovione.com |Tel.: +351
21 982 93 62
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。